Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • Pertuzumab has no clinically significant single-agent activity in castrate patients with HRPC at either of the tested dose levels. This may reflect the continued presence of significant levels of intraprostatic androgen driving androgen receptor signaling.

publication date

  • January 20, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.07.0888

PubMed ID

  • 17235043

Additional Document Info

start page

  • 257

end page

  • 62

volume

  • 25

number

  • 3